Biologics CDMO Market Insights 2025-2034: Growth Forecast and Strategic Priorities

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Biologics CDMO Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the biologics cdmo market has seen explosive growth. The market that was valued at $21.3 billion in 2024 is projected to increase to $24.37 billion in 2025, yielding a compound annual growth rate (CAGR) of 14.4%. The significant increase in the previous years can be traced back to several factors including the escalation in biologics development, cost-effectiveness and adaptability, concentration on core expertise, adherence to regulatory standards and quality assurance, and the worldwide expansion of pharmaceutical supply chains.

Biologics CDMO Market Size Forecast: What's the Projected Valuation by 2029?
The prediction for the biologics CDMO market suggests a fast-paced expansion in the forthcoming years. It is projected to reach a valuation of $42.33 billion in 2029, growing at a CAGR of 14.8%. Factors contributing to this growth during the forecast period include an increased demand for biologic therapies, the emergence of biosimilars and biobetters, growth in biomanufacturing infrastructure development, a shift towards outsourcing difficult processes, emphasis on supply chain robustness and risk reduction, streamlined regulatory harmonization, and fast-tracked approvals. The forecast period will also see notable trends such as expansion of capabilities for providing comprehensive solutions, embracing single-use technologies, continuous manufacturing process integration, and the rise of specialized CDMOs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

What Are the Drivers Transforming the Biologics CDMO Market?
The escalating need for cell and genetic therapy is anticipated to fuel the expansion of the biologic CDMO market in the foreseeable future. Cell and gene therapy represents ground-breaking therapeutic strategies that employ living cells or genetic substances to tackle the root causes of diseases on cell or genetic levels, presenting potential cures for ailments that are challenging or impossible to manage with traditional pharmaceutical products. The increasing attractiveness of cell and gene therapies can be attributed to their potential to introduce unique treatments for illnesses by dealing with basic cellular or genetic reasons. Biologic CDMOs are equipped with the proficiencies needed in dealing with living cells, viral vectors, and genetic substances, enabling the secure and effective production of cell and gene therapies. Moreover, they help biopharmaceutical corporations in navigating the regulatory landscape and overcoming technical difficulties, therefore aiding the transition from research to clinical practice. For example, The American Society of Gene & Cell Therapy (ASGCT), a premier professional membership group based in the United States, reported in January 2023 that the gene, cell, and RNA therapy pipeline grew by 7% in 2022, amounting to a total of 3,726 therapies in the pipeline. Out of these therapies, gene therapies constitute 55%, non-genetically modified cell therapies form 22%, and RNA therapies make up 23%. Consequently, the escalating need for cell and genetic therapy is propelling the expansion of the biologic CDMO market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Long-Term Trends Will Define the Future of the Biologics CDMO Market?
Leading organizations in the biologics CDMO industry are focusing on the development of state-of-the-art solutions like new cell lines to elevate biopharmaceutical production and development proficiencies. This advanced technology creates therapeutic antibodies with amplified potency, addressing hindrances present in immunotherapy research and development. For instance, Lonza Group, a manufacturing company based in Switzerland specializing in biotechnology and pharmaceutical industries, released the GS Effex cell lines in November 2023. These cell lines are manufactured to generate antibodies completely devoid of a sugar molecule called fucose, ensuring improved potency without affecting any other performance aspects. It addresses the complications in immunotherapy research and development, particularly the requirement for enhanced potency of antibody therapeutics. The GS Effex is a stable, scalable, and efficient cell line, proving to be an effective resolution for therapeutic evolution starting from the discovery phase to commercial production.

Which Segments in the Biologics CDMO Market Offer the Most Profit Potential?
The biologics cdmo market covered in this report is segmented -

1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars

Subsegments:
1) By Mammalian: Chinese Hamster Ova*ry (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Which Firms Dominate the Biologics CDMO Market by Market Share and Revenue in 2025?
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Which Regions Offer the Highest Growth Potential in the Biologics CDMO Market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.